Cannabinoid Effect and Safety in Spasticity Following Stroke: A Double-Blind Randomized Placebo-Controlled Study
Marinelli, Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal, Child Health, University Of Genoa, Division Of Clinical Neurophysiology, Irccs Ospedale Policlinico San Martino
throughout the study. Results Recruitment and Participant Flow Among 100 pre-screened patients, 91 met inclusion criteria and were considered for study participation, however 50 patients did not enter the study for the following reasons: refusal to participate (27), transportation difficulties (9), medical decision due to relevant comorbilities or frailty (6), medical decision due to excessive spasticity and need to continue botulinum toxin (4), compliance/reliability issues (3), fear for driving license suspension (1) (Figure 3). Cannabinoid Effect on Outcome Measures The present study does not suggest an improvement in spasticity from the treatment of patients with post-stroke spasticity with nabiximols. Stroke. The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
Tags:
- Nabiximols
- Spasticity
- Placebo
- Multiple sclerosis
- Stroke
- Cannabinoid
- Tetrahydrocannabinol
- Neurotransmitter
- Phases of clinical research
- Placebo-controlled study
- Hypertonia
- Pain
- Randomized controlled trial
- Cannabidiol
- Cannabis (drug)
- Electromyography
- Medical specialties
- Medicine
- Health
- Clinical medicine
- Health care
- Health sciences